Maheswari Muruganandam, MBBS

Maheswari Muruganandam practices at University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico.

Maheswari Muruganandam's NPI, 1548609852, was assigned on June 19, 2013. Maheswari Muruganandam holds New Mexico license MD2019-0277.

Maheswari Muruganandam's primary practice is University of New Mexico Hospital, at 2211 Lomas Boulevard NE, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 272-2111.

Maheswari Muruganandam's primary practice is University of New Mexico Hospital in Albuquerque, New Mexico, part of The University of New Mexico. The medical group on file is UNM Medical Group, Inc.

Dmand AI tracks the electronic health record (EHR) system at each site where Maheswari Muruganandam practices. Vendor and product names are available with a free account.

Rheumatology is Maheswari Muruganandam's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dmand AI has Maheswari Muruganandam's licenses on file in 2 states: New Mexico and Massachusetts.

CMS data shows 129 Medicare services from Maheswari Muruganandam across 3 procedure codes in 2024, for 111 Medicare patients. Medicare paid $7,767 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 111 Medicare patients who saw Maheswari Muruganandam in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have arthritis, and 64% have high blood pressure. 39% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Maheswari Muruganandam's median patient age at 68, with 79% women.

In 2024, Maheswari Muruganandam wrote 1,162 Medicare Part D claims for 187 patients. 73% of them were for generic drugs. CMS names the drug for 1,050 of them, across 20 drugs with 11 or more claims each, at $1,753,472 in total drug cost. In 2023, CMS named 1,151 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Maheswari Muruganandam for performance year 2024, reported as part of a group. Maheswari Muruganandam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Maheswari Muruganandam as offering telehealth.

Dmand AI links 24 papers to Maheswari Muruganandam, published from 2017 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Glucocorticoids, Myositis and Scleroderma, Systemic. Maheswari Muruganandam has published most often in Int J Rheum Dis. Maheswari Muruganandam's most frequent co-authors are Wilmer L. Sibbitt, MD, Sharon E. Nunez, MD and Roderick A. Fields, MD.

CMS Open Payments shows 2 general payments to Maheswari Muruganandam from 1 drug or device company in 2017. Food and beverage make up the largest share, 56% of the total. Genentech, Inc. paid the most, $217.